AACR Abstract embargoed at this time until March 31, but here is the title

LB-038 / 1 - Preclinical development and clinical validation of a whole blood pharmacodynamic marker assay for the BET bromodomain inhibitor ZEN-3694 in metastatic castration-resistant prostate cancer (mCRPC) patients

Presenter/Authors:

Laura Tsujikawa, Karen Norek, Cyrus Calosing, Sarah Attwell, Dean Gilham, Nimisha Sharma, Jennifer Tobin, Michelle Haager, Ravi Jahagirdar, Sanjay Lakhotia, Henrik C. Hansen, Eric Campeau. Zenith Epigenetics, Calgary, AB, Canada

Disclosures:

L. Tsujikawa: ; Zenith Epigenetics. ; Resverlogix. K. Norek: ; Zenith Epigenetics. C. Calosing: ; Zenith Epigenetics. S. Attwell: ; Zenith Epigenetics. D. Gilham: ; Resverlogix. N. Sharma: ; Zenith Epigenetics. J. Tobin: ; Zenith Epigenetics. M. Haager: ; Zenith Epigenetics. R. Jahagirdar: ; Zenith Epigenetics. S. Lakhotia: ; Zenith Epigenetics. H.C. Hansen: ; Zenith Epigenetics. E. Campeau: ; Zenith Epigenetics.